Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease - PubMed (original) (raw)
Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease
C A Smith et al. J Hematother. 1995 Apr.
Abstract
EBV-induced lymphoproliferative disease (EBV-LPD) is a disorder most commonly associated with the immunocompromise that follows allogeneic organ transplantation. In patients receiving T cell-depleted bone marrow from HLA-mismatched or HLA-matched unrelated donors, the incidence of EBV-LPD is particularly high, ranging from 5 to 30%. Administration of EBV-specific cytotoxic T lymphocytes may be one means of preventing and treating this disease. We now describe a method that allows the routine and timely preparation of large numbers of such cells to allow their safe administration to bone marrow transplant recipients. We also describe how these cells may be genetically marked before infusion, to determine their fate and disposition in vivo.
Similar articles
- Virus-specific cytotoxic T lymphocytes as prophylaxis for Epstein-Barr virus lymphoproliferative disease in pediatric bone marrow transplant recipients.
Norville R, Nance D, Cheshire S. Norville R, et al. J Pediatr Oncol Nurs. 1997 Oct;14(4):194-201. doi: 10.1177/104345429701400403. J Pediatr Oncol Nurs. 1997. PMID: 9322393 Review. - Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells.
Gustafsson A, Levitsky V, Zou JZ, Frisan T, Dalianis T, Ljungman P, Ringden O, Winiarski J, Ernberg I, Masucci MG. Gustafsson A, et al. Blood. 2000 Feb 1;95(3):807-14. Blood. 2000. PMID: 10648390 - Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation.
Rooney CM, Smith CA, Ng CY, Loftin S, Li C, Krance RA, Brenner MK, Heslop HE. Rooney CM, et al. Lancet. 1995 Jan 7;345(8941):9-13. doi: 10.1016/s0140-6736(95)91150-2. Lancet. 1995. PMID: 7799740 - The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation.
Lucas KG, Small TN, Heller G, Dupont B, O'Reilly RJ. Lucas KG, et al. Blood. 1996 Mar 15;87(6):2594-603. Blood. 1996. PMID: 8630428 - Adoptive cell therapy with donor lymphocytes for EBV-associated lymphomas developing after allogeneic marrow transplants.
O'Reilly RJ, Lacerda JF, Lucas KG, Rosenfield NS, Small TN, Papadopoulos EB. O'Reilly RJ, et al. Important Adv Oncol. 1996:149-66. Important Adv Oncol. 1996. PMID: 8791134 Review. No abstract available.
Cited by
- Transposon-modified antigen-specific T lymphocytes for sustained therapeutic protein delivery in vivo.
O'Neil RT, Saha S, Veach RA, Welch RC, Woodard LE, Rooney CM, Wilson MH. O'Neil RT, et al. Nat Commun. 2018 Apr 10;9(1):1325. doi: 10.1038/s41467-018-03787-8. Nat Commun. 2018. PMID: 29636469 Free PMC article. - Complementation of antigen-presenting cells to generate T lymphocytes with broad target specificity.
Ngo MC, Ando J, Leen AM, Ennamuri S, Lapteva N, Vera JF, Min-Venditti A, Mims MP, Heslop HE, Bollard CM, Gottschalk S, Rooney CM. Ngo MC, et al. J Immunother. 2014 May;37(4):193-203. doi: 10.1097/CJI.0000000000000014. J Immunother. 2014. PMID: 24714353 Free PMC article. - Virus and autoantigen-specific CD4+ T cells are key effectors in a SCID mouse model of EBV-associated post-transplant lymphoproliferative disorders.
Linnerbauer S, Behrends U, Adhikary D, Witter K, Bornkamm GW, Mautner J. Linnerbauer S, et al. PLoS Pathog. 2014 May 22;10(5):e1004068. doi: 10.1371/journal.ppat.1004068. eCollection 2014 May. PLoS Pathog. 2014. PMID: 24853673 Free PMC article. - Evaluation of novel Epstein-Barr virus-derived antigen formulations for monitoring virus-specific T cells in pediatric patients with infectious mononucleosis.
Fischer F, Mücke J, Werny L, Gerrer K, Mihatsch L, Zehetmaier S, Riedel I, Geisperger J, Bodenhausen M, Schulte-Hillen L, Hoffmann D, Protzer U, Mautner J, Behrends U, Bauer T, Körber N. Fischer F, et al. Virol J. 2024 Jun 14;21(1):139. doi: 10.1186/s12985-024-02411-0. Virol J. 2024. PMID: 38877590 Free PMC article. - Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes.
Naik S, Nicholas SK, Martinez CA, Leen AM, Hanley PJ, Gottschalk SM, Rooney CM, Hanson IC, Krance RA, Shpall EJ, Cruz CR, Amrolia P, Lucchini G, Bunin N, Heimall J, Klein OR, Gennery AR, Slatter MA, Vickers MA, Orange JS, Heslop HE, Bollard CM, Keller MD. Naik S, et al. J Allergy Clin Immunol. 2016 May;137(5):1498-1505.e1. doi: 10.1016/j.jaci.2015.12.1311. Epub 2016 Feb 24. J Allergy Clin Immunol. 2016. PMID: 26920464 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Other Literature Sources
Medical
Research Materials